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Abstract
Introduction: The Endotoxin Activity Assay (EAA) is a useful test to risk stratify patients with severe sepsis and
assess for Gram negative infection. However, the significance of intermediate levels of EAA (0.4-0.59) at the bedside
has not been well elucidated. The purpose of this study was to interpret intermediate EAA levels in clinical
practice.
Methods: This retrospective observational study included all adult patients with suspected sepsis admitted to our
medico-surgical intensive care unit (ICU) in whom EAA was measured from July 2008 to September 2011. Data
collected included EAA, white blood cell (WBC) count and differential, C-reactive protein (CRP), procalcitonin (PCT)
and bacterial cultures. Data were analyzed by comparative statistics.
Results: Two hundred and ten patients were studied. Ninety two (43%) patients had culture documented gram
negative infection. Patients with Gram-negative organisms in cultures had significantly higher EAA levels (0.47, IQR
0.27) than those without any Gram-negative organisms in cultures (0.34, IQR 0.22) (p < 0.0001). For patients with
intermediate EAA levels (0.40 to 0.59), PCT levels and presence of left shift of WBC significantly differed between
patients with Gram negative organisms in their blood or other cultures and those who had no organisms in any of
the cultures (4.9 versus 1.7 ng/mL, p < 0.05; 57.9 versus 18.9%, p < 0.0004, respectively).
Conclusions: We confirm that high levels of EAA in our cohort of patients with suspected sepsis are strongly
associated with gram negative infection. In those patients with intermediate elevation in EAA levels, use of PCT
and WBC differential can provide additional diagnostic value to clinicians at the bedside.
Introduction
Endotoxin, a key component of the membrane of Gram-
negative bacteria, is the most well-studied marker and
mediator of sepsis. The Endotoxin Activity Assay
(EAA™; Spectral Diagnostics Inc., Toronto, ON, Canada)
is a rapid in vitro diagnostic test that is based on the
reaction of neutrophils to endotoxin complexed with an
anti-endotoxin antibody and that allows measurement of
endotoxin activity levels in whole blood at the bedside
[1-3]. The Multi-center Endotoxin Detection In Critical
illness (MEDIC) trial assessed the characteristics of the
EAA as a clinical test [4]. Firstly, to establish cutoff
values, the assay was validated in 97 healthy controls. In
this population, there was no volunteer with an EAA
value of greater than 0.6, and the EAA was less than 0.4
in 93% of healthy volunteers. When conducted in 857
patients with suspected sepsis on admission to the inten-
sive care unit (ICU), the MEDIC trial demonstrated a
high value of EAA (>0.60), which was associated with an
odds ratio of 3.0 for the development of severe sepsis [4].
Moreover, an EAA in the low range (<0.4) had a negative
predictive value of 95.1% from risk of culture-proven
Gram-negative infection, whereas an EAA in the high
range (>0.6) was associated with an odds ratio of 5.3 for
* Correspondence: ayaguchi@ccmc.twmu.ac.jp
1Department of Critical Care and Emergency Medicine, Tokyo Women’s
Medical University, 8-1 Kawadacho, Shinjuku, Tokyo 1628666, Japan
Full list of author information is available at the end of the article
Yaguchi et al. Critical Care 2012, 16:R88
http://ccforum.com/content/16/3/R88
© 2012 Yaguchi et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Gram-negative infection [4]. However, the clinical utility
of EAA of between 0.4 and 0.59 was not well established
by the MEDIC trial. Further clinical and diagnostic
approaches are required to precisely determine the diag-
nosis of Gram-negative infections in patients with inter-
mediate EAA levels. In clinical practice, we need to make
an urgent diagnosis to allow the initiation of appropriate
therapies such as targeted antibiotics before we obtain
the results of cultures [5]. In addition, during the clinical
course of patients in the ICU, the change or discontinua-
tion of antibiotic therapy has to be quickly decided.
Thus, the purpose of the present study was to elucidate
the practical utility of EAA test results in the intermedi-
ate range alone and combined with other routinely and
rapidly available bedside tests in ICU patients with sus-
pected sepsis.
Materials and methods
The study design was a single-center retrospective obser-
vational analysis of all adult patients who had sepsis and
who were admitted to our tertiary academic medico-
surgical ICU and in whom EAA was performed from July
2008 to September 2011. Sepsis was diagnosed by sus-
pected infection such as by radiologic or clinical data,
fever (>38.3°C) or hypothermia (<36.0°C), leukocytosis
(white blood cell (WBC) count of greater than 12,000/
µL) or leukopenia (WBC count of less than 4,000/µL), or
plasma C-reactive protein (CRP) (>1.5 mg/dL3) [6].
Exclusion criteria were age of less than 18 years old and
administration of steroids or other immunosuppressants
[7]. Clinical and microbiological data of each patient
were collected from electrical medical archives. The base-
line characteristics collected were age, gender, body
temperature (in degrees Celsius), WBC count and differ-
ential, CRP levels (normal is less than 0.33 mg/dL), pro-
calcitonin (PCT) levels (normal is less than 0.5 ng/mL),
and EAA (EAA™) and microbiologic culture results
from any site. In keeping with our routine ICU practice,
a split sample of whole blood was sent for blood culture
at the time the EAA was drawn. Other cultures from
sites of suspected infection were similarly sent simulta-
neously with EAA values. The EAA was sent (also our
usual practice) on those patients with suspected sepsis of
unknown origin of infection. For analysis, WBC count
and differential and CRP levels were used from the time
point closest to when the EAA was performed. PCT was
measured on the identical blood draw as EAA. We deter-
mined that the presence of Gram-negative organisms in
culture was indicative of infection if they were positive in
blood, ascites, pleural effusion, or wound cultures. When
culture results showed less than 1 + in sputum or less
than × 104 in urine, we decided they were just coloniza-
tions.. The study protocol was approved by the Tokyo
Women’s Medical University institutional review board,
and the need for patient consent was waived because this
study is a retrospective observational analysis of patient
data from medical archives.
Statistical analysis
All values are expressed as median and interquartile
ranges (IQRs). Data were analyzed by Kruskal-Wallis
test, Mann-Whitney U test, chi-squared test, and Fisher
exact probability test. A P value of less than 0.05 was
considered to be statistically significant.
Results
Patient characteristics
Two hundred ten patients (141 men and 69 women;
median age of 71 years, IQR of 55 to 82) were
included in this study. The characteristics of patients
are shown in Table 1. One hundred sixty-four patients
(78%) survived to ICU discharge, and 46 (22%) patients
died during their ICU stay. Twenty-seven patients had
high EAA levels (≥0.6), 79 patients had intermediate
levels (0.40 to 0.59), and 104 patients had low EAA
levels (<0.4). For those patient groups in each EAA
range, there were no significant differences in age, gen-
der, temperature, ICU mortality, WBC count or differ-
ential, and CRP levels. PCT levels, the presence of
Gram-negative organisms in any cultures, and Gram-
negative organisms in blood were statistically different
between high, intermediate, and low levels of EAA (4.7
versus 1.7 versus 1.0 ng/mL, P = 0.0003; 70.4% versus
51.3% versus 27.4%, P <0.0001; and 25.9% versus 10%
versus 3.8%, P <0.0001, respectively). Although 20
patients in our cohort received polymyxin B hemoper-
fusion as part of their therapy, none received this
treatment prior to laboratory investigations that
included the EAA.
EAA levels and Gram-negative infection
EAA levels in patients with Gram-negative organisms in
any culture (n = 92) and without any Gram-negative
organisms in any cultures (n = 118) were significantly
different (0.47, IQR 0.27 versus 0.34, IQR 0.22, P
<0.0001) (Figure 1). There were also statistically signifi-
cant differences between patients with Gram-negative
organisms in blood (n = 21) and those without any
Gram-negative organisms in any of the cultures (n =
118) - 0.50 (IQR 0.44 to 0.71) versus 0.34 (IQR 0.26 to
0.48), respectively, P = 0.0007 - and between patients
with Gram-negative organisms in culture that were not
bacteremic (n = 71) and those without any Gram-nega-
tive organisms in any of the cultures (n = 118) - 0.45
(IQR 0.32 to 0.58) versus 0.34 (IQR 0.26 to 0.48),
respectively, P = 0.001 - (Figure 2).
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Table 1 Characteristics of patients
Low EAA (<0.40) Intermediate EAA (0.4-0.59) High EAA (≥0.6) P value
Number 104 79 27
Age (range), years 67.5 (19-96) 71 (23-97) 76 (25-92) 0.59
Percentage of males 69.8 60 74 0.25
Body temperature (range), °C 37.0 (36.4-37.6) 37.2 (34-39.2) 37.3 (36-39.2) 0.51
White blood cells (IQR),/mm3 12,030 (8,720-18,150) 12,030 (7,080-17,053) 11,550 (2,522-15,888) 0.22
Stab neutrophils (IQR), percentage 9.0 (2.4-21.4) 7.5 (2.0-23.0) 10.0 (2.8-37.8) 0.45
Segmented neutrophils (IQR), percentage 78.5 (66.0-84.6) 78.0 (59.8-85.5) 71.0 (36.1- 84.8) 0.19
Left shift of neutrophils, percentage 37.7 36.3 44.4 0.77
C-reactive protein (IQR), mg/dL 11.6 (7.0-19.6) 12.2 (6.9-19.9) 13.2 (6.4-21.2) 0.06
Procalcitonin (IQR), ng/mL 1.0 (0.2-5.2) 1.7 (0.3-7.7) 4.7 (1.6-24.8) 0.003
Gram-negative organism, percentage 27.4 51.3 70.4 <0.0001
Gram-negative bacteremia, percentage 3.8 10 25.9 <0.0001
ICU mortality, percentage 17.3 22.5 37 0.13














Figure 1 Endotoxin Activity Assay (EAA) values in patients with Gram-negaitve infection and no infections. Patients with no Gram-
negative organisms in any culture (n = 118) (white square boxes) and with Gram-negative organisms in some cultures (n = 92) (black square
boxes). The horizontal bar in each box indicates the median value, and the box indicates the interquartile ranges (IQRs). The vertical lines
indicate 1.5 times the IQR. All values outside these lines are shown as black or white spots. *P < 0.0001.
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Organisms and intermediate EAA
Table 2 shows the distribution of bacterial organisms in
cultures and associated EAA levels. Of the 113 culture
examinations of patients with intermediate EAA levels,
10 blood cultures revealed Gram-negative organisms
and 9 blood cultures were positive for Gram-positive
organisms. In sputum, 32 cultures had Gram-negative
species, 17 cultures had Gram-positive species, and 5
cultures were positive for fungus. There were 9 cultures
from wound or abscess, 17 cultures from urine, and 3
cultures from ascites of Gram-negative organisms in the
intermediate group.
Patient characteristics in the intermediate EAA levels (0.4
to 0.59)
There was no statistically significant difference for age,
gender, body temperature, WBC count, CRP levels, and
EAA values between patients with Gram-negative
organisms detected in cultures (n = 42) and those with-
out any Gram-negative organisms in any cultures (n =
37) (Table 3). The percentage of stab and segmented
neutrophils, left shift of neutrophils, and PCT levels
were statistically different: 18% (IQR 3.5% to 32.0%) ver-
sus 3.5% (IQR 1.4% to 7.8%), P = 0.0006; 65.0% (IQR
48.5% to 78.5%) versus 86.0% (IQR 70.5% to 86.5%), P =
0.0004; 57.9% versus 18.9%, P = 0.0004; and 4.9 (IQR
0.4 to 13.8) versus 1.7 (IQR 0.2 to 3.0) ng/mL, P = 0.05,
respectively.
Combining PCT levels, left shift of neutrophils, and Gram-
negative organisms in patients with intermediate EAA
levels (0.4 to 0.59)
Patients with EAA levels of 0.4 to 0.59 were divided into
two groups according to the appearance of left shift of
neutrophils or PCT values of more than 5 ng/mL or


















Figure 2 Endotoxin Activity Assay (EAA) values and in patients with Gram-negative bacteremia and invections. Patients with no Gram-
negative organisms in any cultures (n = 118) (white square boxes), with Gram-negative organisms in some cultures without blood (n = 71) (gray
square boxes), and with Gram-negative organisms in blood (n = 21) (black square boxes). The horizontal bar in each box indicates the median
value, and the box indicates the interquartile range (IQR). The vertical lines indicate 1.5 times the IQR. All values outside these lines are shown as
black, gray, or white spots. *P < 0.001.
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Table 2 Distributions of the organism in the cultures and the levels of Endotoxin Activity Assay
Culture sample Organism Low EAA (<0.4) Intermediate
EAA (0.4-0.59)
High EAA (≥0.6)
Blood Gram-negative Escherichia coli 3 4
Klebsiella pneumoniae 4 4
Klebsiella oxytoca 1
Bacteroides fragilis 1 1 1
Pseudomonas aeruginosa 1
Serratia marcescens 1
Gram-positive Streptococcus pyogenes 2 1 1
Staphylococcus epidermidis 1 1 1
MSSA 4 6 1
MRSA 5 1
Enterococcus faecalis 1
Suptum Gram-negative Escherichia coli 2 2 1
Pseudomonas aeruginosa 3 4 4
Enterobacter aergenes 2
Enterobacter cloacae 1 2
Klebsiella pneumoniae 1 9 4
Klebsiella oxytoca 1
Acinetobacter 2 2 1
Serratia marcescens 4 3 2
Stenotrophomonas maltophilia 4 8 2
Proteus mirabilis 2
Haemophilus influenzae 1
Gram-positive Streptococcus pneuminiae 6 2
Staphylococcus aureus 2 2
Corynebacterium sp. 2 2
MSSA 13 3
MRSA 9 7 4
Enterococcus faecalis 3 1 2
Fungus Candida albicans 18 5
Urine Gram-negative Escherichia coli 3 7 2
Pseudomonas aeruginosa 1 5 2
Klebsiella pneumoniae 4 3 3






Fungus Candida albicans 3 3
Ascites Gram-negative Escherichia coli 1 2
Bacteroides fragilis 1
Pleural effusion Gram-negative Pseudomonas aeruginosa 1
Klebsiella pneumoniae 2
Gram-positive MRSA 3 2
Abscess, wound Gram-negative Pseudomonas aeruginosa 1 1
Bacteroides fragilis 2 3
Klebsiella pneumoniae 1 3
Escherichia coli 2 2 1
Gram-positive MSSA 2 1 1
MRSA 3
Streptococcus 5 1
Enterococcus faecalis 2 2
EAA, Endotoxin Activity Assay; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus.
Yaguchi et al. Critical Care 2012, 16:R88
http://ccforum.com/content/16/3/R88
Page 5 of 8
compared between the two groups (Table 4). There
were 36 patients (45.6%) with left shift of neutrophils or
PCT levels of more than 5 ng/mL or both and 43
patients (54.4%) without left shift of neutrophils or PCT
levels of less than 5 ng/mL or both. Of the 36 patients,
25 patients were positive for Gram-negative organisms
in any culture; of the 43 patients without left shift of
neutrophils or PCT levels of less than 5 ng/mL or both,
26 patients were negative for Gram-negative organisms
in any culture. A statistically significant difference was
shown for the presence of Gram-negative organisms
between the groups (P = 0.0008). The positive predictive
value (PPV) was 59.5%, whereas the negative predictive
value (NPV) was 70.2%. In the low level of EAA, the
PPV and the NPV were 29.1% and 72.7%, respectively.
In the high level of EAA, the PPV and the NPV were
82.4% and 50.0%, respectively.
Discussion
This study confirms that EAA levels are significantly
increased in patients with culture-proven Gram-negative
infection. In the low-EAA group, Gram-negative organ-
isms were found in sputum, urine, ascites, pleural effusion,
and wounds but rarely in blood cultures. This result is
consistent with that of previously reported studies [3,4]. A
particular difference of our work is that the EAA measure-
ment and other laboratory data as well as blood cultures
were done on identical blood samples. Therefore, the pre-
sent results could be more reliable than those of previous
studies, which showed differences between the results of
the EAA and incidence of documented Gram-negative
infections [3,8]. Similar to previous investigations, our
study is limited in that the study patients had the decision
whether to perform an EAA made on the basis of clinical
bedside assessment of suspicion of sepsis rather than
studying all ICU patients. Several patients had already
received empiric antibiotics in their clinical course and
this may confound the results given that the potential
impact of different antibiotics on different organisms in
terms of changing lipopolysaccharide levels is not well
understood. In clinical practice, we usually have to deter-
mine whether our patient has sepsis and whether antibio-
tics should be initiated, changed, or stopped in empirical
cases without any documented microbiology. Therefore,
EAA may be expected to have additional utility as one of
the tools for diagnosis of sepsis. Recently, several studies
have shown the utility of EAA in the evaluation of the
severity, prognosis, and indications of therapy for sepsis
[3,9-14]. It has been generally established that high EAA
levels (≥0.6) can help rule in sepsis due to Gram-negative
infections and that patients with low EAA levels (<0.4)
have a low risk of sepsis due to Gram-negative infection.
The issue of the interpretation of EAA results in the inter-
mediate range remains. Clinically, these patients may have
sepsis due to Gram-negative infection or other sources of
infection with translocation of endotoxin from the gastro-
intestinal tract [15]. The patients may also have endotoxe-
mia as a result of translocation of endotoxin from another
disease process. Risk of endotoxemia has been shown
in patients with trauma, major burns, transplantion,





organism in any cultures
(n = 37)
P value
Age (range), years 76 (23-97) 71.0 (32-92) 0.10
Percentage of males 69 51 0.11
Body temperature (range), °C 37.4 (34.6-39.2) 37.4 (34.0-39.0) 0.98
White blood cells (IQR),/mm3 11,070 (6,130-17,480) 12,410 (6,740-16,290) 0.95
Stab neutrophils (IQR), percentage 18 (3.5-32.0) 3.5 (1.4-7.8) 0.0006
Segmented neutrophils (IQR), percentage 65.0 (48.5-78.5) 83.0 (70.5-86.5) 0.0004
Left shift of neutrophils, percentage 57.9 18.9 0.0004
C-reactive protein (IQR), mg/dL 13.1 (6.0-21.4) 13.7 (6.6-19.4) 0.91
Procalcitonin (IQR), ng/mL 4.9 (0.4-13.8) 1.7 (0.2-3.0) 0.05
EAA value (IQR) 0.5 (0.45-0.53) 0.49 (0.45-0.52) 0.88
EAA, Endotoxin Activity Assay; IQR, interquartile range.
Table 4 Left shift of neutrophils and procalcitonin levels and Gram-negative organism infection in the intermediate
Endotoxin Activity Assay level
Gram-negative organism in cultures
(n = 42)
No Gram-negative organism in any cultures
(n = 37)
Left shift (+) or PCT (≥ 5.0 ng/mL) or both 25 11
Left shift (−) or PCT (<5.0 ng/mL) or both 17 26
P = 0.008. PCT, procalcitonin.
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pancreatitis, or other conditions that may predispose to
gut translocation [15-17]. Our study showed that PCT
levels and the percentage of stab neutrophils were
increased in patients with documented Gram-negative
organisms in comparison with those without any docu-
mented Gram-negative organisms. Therefore, we com-
bined PCT levels and left shift of neutrophils with EAA to
evaluate for diagnosis of Gram-negative sepsis in the
patient group with intermediate levels of EAA. Plasma
PCT level alone is limited in its diagnostic ability for sepsis
at the bedside, as are older tests like WBC differential [6].
There are a few studies regarding the correlation between
EAA and PCT; one study shows that there are concomi-
tant elevations of EAA levels and PCT in patients with
sepsis [18], whereas another study shows no correlation
between EAA and PCT [19]. The former study showed
that EAA levels (>0.60) and PCT (>2.0 ng/mL) had a posi-
tive agreement with a clinical diagnosis of severe sepsis
[18]. In those patients with confirmed Gram-negative
infection, our study demonstrates a strong correlation
between EAA in the high range and PCT. Furthermore,
we show that in patients who have intermediate levels of
EAA (0.4 to 0.59), the addition of PCT levels and presence
of a left shift of neutrophils can be useful to diagnose sep-
sis due to Gram-negative infection.
Conclusions
The EAA is a rapid and simple test that is used at the
bedside to evaluate patients with suspected sepsis for
endotoxemia in clinical practice. High EAA levels (≥0.6)
can be used to diagnose sepsis due to Gram-negative
infections, and low EAA levels (<0.4) can be used to
rule out Gram-negative infections. Combining plasma
PCT levels and left shift of neutrophils can aid clinicians
at the bedside in interpreting the meaning of an EAA in
the intermediate range. Further research is necessary to
prospectively validate this model in the ICU setting.
Key messages
• High Endotoxin Activity Assay (EAA) levels (≥0.6) can
be used to help diagnose sepsis due to Gram-negative
infections.
• Low EAA levels (<0.4) can be used to rule out
Gram-negative infections.
• Procalcitonin levels and presence of shift to the left
of white blood cells (WBCs) show differences between
Gram-negative infection and no Gram-negative infection
in intermediate EAA levels.
• Combining procalcitonin and differential of WBCs
can help to diagnosis sepsis in intermediate EAA levels.
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